Abstract

The Contractor will develop TiterQuil-1055, a semi-synthetic saponin adjuvant analog of QS-21, for the purpose of improving the immunogenicity of commercially available flu vaccines (Fluzone (Sanofi Pasteur), Fluvirin (Seqirus), and Flublok (Protein Sciences)).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research – Phase I (N43)
Project #
272201700066C-0-0-1
Application #
9574356
Study Section
Project Start
2017-08-01
Project End
2018-07-31
Budget Start
Budget End
Support Year
Fiscal Year
2017
Total Cost
Indirect Cost

  Institution

Name
Adjuvance Technologies, Inc.
Department
Type
DUNS #
831676247
City
New York
State
NY
Country
United States
Zip Code
10010